Home » Posts tagged with » BioNTech
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech

Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in participants of a phase 3 trial who were not previously exposed to the SARS-CoV-2 infection. The data is based on the first interim efficacy analysis from the phase 3 clinical […]

BioNTech to acquire Novartis’ Marburg manufacturing plant to expand production of COVID-19 vaccine candidates

Biopharmaceutical New Technologies (BioNTech) has agreed to acquire a GMP certified manufacturing facility in Marburg, Germany from Novartis to expand the production capacity of its BNT162 COVID-19 vaccine candidates. The financial terms of the deal were not revealed by the parties. BioNTech said that the production capacity of its five mRNA COVID-19 vaccine candidates under […]

Continue reading …
Pfizer, BioNTech sign deal to supply BNT162 Covid-19 vaccine to Canada

Pfizer and BioNTech have signed an agreement with the Canadian government to supply their mRNA-based BNT162 vaccine candidate against SARS-CoV2, depending on clinical success and approval from Health Canada. Financial details of the deal were not revealed. However, the terms in the deal were based on the timing of delivery and the volume of the […]

Continue reading …
BNT162 COVID-19 vaccine candidate : US govt signs $2bn supply deal with Pfizer and BioNTech

Pfizer and BioNTech have bagged a $1.95 billion deal with the US government for supplying 100 million doses of their jointly developed BNT162 COVID-19 vaccine candidate. Recently, the two pharma companies were granted the fast track designation from the US Food and Drug Administration (FDA) for BNT162b1 and BNT162b1 vaccines, which are two of the […]

Continue reading …
BNT162b1 and BNT162b2 Covid-19 vaccine candidates get FDA fast track status

Pfizer and BioNTech said that BNT162b1 and BNT162b2, two vaccine candidates developed to give protection against the SARS-CoV-2 virus have been given the fast track designation from the USFood and Drug Administration (FDA). The two vaccine candidates are part of the four investigational vaccine candidates that are being jointly developed by the companies under their […]

Continue reading …
BioNTech, Pfizer join forces to develop mRNA-based flu vaccines

BioNTech, a German biotechnology company, has joined forces with US pharma giant Pfizer to develop mRNA-based flu vaccines as part of a $425 million multi-year research and development (R&D) collaboration. As per the terms of the deal, BioNTech and Pfizer will jointly take up research and development activities for advancing mRNA-based vaccines to prevent influenza […]

Continue reading …